An issue of selecting of immunobiological therapy of bronchial asthma
- Authors: Ilina NI1
-
Affiliations:
- NRC Institute of Immunology FMBA of Russia
- Issue: Vol 16, No 1 (2019)
- Pages: 9-12
- Section: Articles
- URL: https://journals.rcsi.science/raj/article/view/120433
- DOI: https://doi.org/10.36691/RJA15
- ID: 120433
Cite item
Full Text
Abstract
The results of indirect treatment comparison of the efficacy of anti-Il-5 pathway therapies in severe eosinophilic asthma on the basis of network meta-analysis and Cochrane review are presented in the article.
Full Text
##article.viewOnOriginalSite##About the authors
N I Ilina
NRC Institute of Immunology FMBA of Russia
Email: instimmun@yandex.ru
главный врач, зам. директора по лечебной работе, доктор медицинских наук, профессор.
References
- Инструкция по медицинскому применению лекарственного препарата Нукала. https://grls.rosminzdrav.ru/Grls_ View_v2.aspx?routingGuid=c9500b78-9cf6-45c9-8336-16ef-5348b722&t= Дата обращения: 26.10.2018
- Инструкция по медицинскому применению лекарственного препарата Синкейро. https://grls.rosminzdrav. ru/Grls_View_v2.aspx?routingGuid=d2f201db-73ab-465c-afb8-3a04f78e1608&t=. Дата обращения: 26.10.2018
- Ortega HG, Yancey SW, Mayer B., Gunsoy NB, Keene ON, Bleecker ER et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549-556.
- Ortega HG. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl J. Med. 2014;371:1198-1207.
- Pavord ID, Korn S., Howarth P., Bleecker eR, Buhl R., Keene N. et al. Mepolizumab for severe eosinophilic asthma (DREAM) : a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.
- Castro M., Zangrilli J., Wechsler ME, Bateman ED, Brusselle GG, Bardin P. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomized, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355-366.
- Bleecker ER, FitzGerald JM, Chanez P., Papi A., Weinstein SF, Barker P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting ß2-agonists (SIROCCO): a randomized, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115-2127.
- FitzGerald JM, Bleecker ER, Nair P., Korn S., Ohta K., Lommatzsch M. et al. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128-2141.
- Cabon Y., Molinari N., Marin G., Vachier I., Gamez AS, Chanez P. et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47:129-138.
- Farne HA, Wilson A., Powell C., Bax L., Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.
- Castro M., Mathur S., Hargreave F., Boulet LP, Xie F., Young J. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J. Respir Crit Care Med. 2011;184:1125-1132.
- Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J., Nelsen LM et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomized, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390-400.
- Bjermer L., Lemiere C., Maspero J., Weiss S., Zangrilli J., Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789-798.
- Corren J., Weinstein S., Janka L., Zangrilli J., Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799-810.
- FitzGerald JM, Bleecker ER, Menzies-Gow A., Zangrilli JG, Hirsch I., Metcalfe P. et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis ofthe SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6:51-64.
- Brusselle G., Germinaro M., Weiss S., Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39-45.
- Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin Epidemiol. 1997;50:683-691.
- Методические рекомендации по проведению непрямых сравнений лекарственных препаратов. ФГБУ «ЦЭККМП» Минздрава России. М., 2017
- DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7;177-188.
- Rucker G., Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.
![](/img/style/loading.gif)